Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Summary

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to \<18 years of age with invasive aspergillosis (IA).

Timeline

Start

2020-07-02

Primary completion

2023-12-18

Completion

2023-12-18

Publications

• Kang HJ, Arrieta AC, Dhooge C, Kelemen A, Macias-Parra M, Aranda L, Dinikina YV, Kassis I, Cesaro S, Shepherd A, Shah AK, Mackey T, Waskin H, Johnson MG. Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease. Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0130525. doi: 10.1128/aac.01305-25. Epub 2026 Jan 27.

Drugs

Indications